Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve

Pîbarot, Philippe; Hahn, Rebecca T.; Weissman, Neil J.; Arsenault, Marie; Beaudoin, Jonathan; Bernier, Martin; Dahou, Abdellaziz; Khalique, Omar; Asch, Federico M.; Toubal, Oumhani; Leipsic, Jonathon; Blanke, Philipp; Zhang, Feifan; Parvataneni, Rupa; Alu, Maria; Herrmann, Howard C.; Makkar, Raj; Mack, Michael J.; Smalling, Richard W.; Leon, Martin B.; Thourani, Vinod H.; Kodali, Susheel

doi:10.1001/jamacardio.2017.3425

Cited by 165 publications

(79 citation statements)

References 25 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This might be due to the low AR rates, with mostly none/trace or mild AR severity. However, this lack of association between mild AR and clinical outcomes is in accordance with the FRANCE-2 Registry and the PART-NER II SAPIEN 3 trial [25,26].…”

Section: Discussionsupporting

confidence: 70%

Randomised comparison of a balloon-expandable and self-expandable valve with quantitative assessment of aortic regurgitation using magnetic resonance imaging

et al. 2020

View full text Add to dashboard Cite

Introduction Transcatheter aortic valve implantation (TAVI) is a safe and effective treatment for inoperable, intermediate-or high-risk patients with severe symptomatic aortic stenosis and has been associated with excellent clinical outcomes. A clinically relevant remaining problem is aortic regurgitation (AR) post-TAVI, which is associated with increased mortality. Therefore, we conducted a prospective randomised trial to assess the safety and efficacy of a first-generation self-expandable valve (SEV; CoreValve) and a third-generation balloon-expandable valve (BEV; Sapien 3) with respect to clinical outcomes and AR

show abstract

Section: Discussionsupporting

confidence: 70%

Randomised comparison of a balloon-expandable and self-expandable valve with quantitative assessment of aortic regurgitation using magnetic resonance imaging

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patients undergoing new pacemaker implantation following TAVR have a 30-day heart failure readmission rate of 22.4% compared with 16.1% for patients without a new pacemaker 13. For patients enrolled in the Placement of AoRTic TraNscathetER Valves (PARTNER II) trial, TAVR patients with moderate or greater paravalvular aortic regurgitation had an HR of 2.27 (95% CI 1.31 to 3.94) for 1-year readmission compared with patients with mild or no paravalvular regurgitation 25. A single study confirmed the relationship between moderate or greater pre-TAVR TR and 30-day readmission 26.…”

Section: Introductionmentioning

confidence: 99%

Identifying patients likely to be readmitted after transcatheter aortic valve replacement

Goldsweig

Aronow

2019

Heart

View full text Add to dashboard Cite

Hospital readmission following transcatheter aortic valve replacement (TAVR) contributes considerably to the costs of care. Readmission rates following TAVR have been reported to be as high as 17.4% at 30 days and 53.2% at 1 year. Patient and procedural factors predict an increased likelihood of readmission including non-transfemoral access, acute and chronic kidney impairment, chronic lung disease, left ventricular systolic dysfunction, atrial fibrillation, major bleeding and prolonged index hospitalisation. Recent studies have also found the requirement for new pacemaker implantation and the severity of paravalvular aortic regurgitation and tricuspid regurgitation to be novel predictors of readmission. Post-TAVR readmission within 30 days of discharge is more likely to occur for non-cardiac than cardiac pathology, although readmission for cardiac causes, especially heart failure, predicts higher mortality than readmission for non-cardiac causes. To combat the risk of readmission and associated mortality, the routine practice of calculating and considering readmission risk should be adopted by the heart team. Furthermore, because most readmissions following TAVR occur for non-cardiac reasons, more holistic approaches to readmission prevention are necessary. Familiarity with the most common predictors and causes of readmission should guide the development of initiatives to address these conditions proactively.

show abstract

“…Patients with at least moderate PVR had higher 1‐year mortality (HR, 2.40; P = 0.005) and the composite of mortality/re‐hospitalization (HR, 2.35; P < 0 .001). Patients with moderate PVR at 30 days had a decrease in PVR severity at 1 year …”

Section: Complicationsmentioning

confidence: 96%

Transcatheter aortic valve replacement: The year in review 2017

Thakur

Nazif

Khalique

et al. 2018

J Interven Cardiology

Self Cite

View full text Add to dashboard Cite

This article is a continuation of our previously published annual reviews of transcatheter aortic valve replacement (TAVR). In 2017, TAVR further established a foothold in the management of intermediate risk patients with the publication of SURTAVI trial. Randomized trials also addressed the use of cerebral protection during TAVR and single versus dual antiplatelet therapy after TAVR. Newer generation valve systems continued to be studied for their efficacy and safety. This paper summarizes the major studies published in 2017.

show abstract

Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve

Abstract: clinicaltrials.gov Identifier: NCT01314313.

Cited by 165 publications

References 25 publications

Randomised comparison of a balloon-expandable and self-expandable valve with quantitative assessment of aortic regurgitation using magnetic resonance imaging

Randomised comparison of a balloon-expandable and self-expandable valve with quantitative assessment of aortic regurgitation using magnetic resonance imaging

Identifying patients likely to be readmitted after transcatheter aortic valve replacement

Transcatheter aortic valve replacement: The year in review 2017

Contact Info

Product

Resources

About